Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Protagonist Therapeutics ...

    NASDAQ: PTGX · Real-Time Price · USD
    54.66
    -1.71 (-3.03%)
    At close: Jun 16, 2025, 3:59 PM
    55.00
    0.63%
    Pre-market: Jun 17, 2025, 05:10 AM EDT

    Protagonist Therapeutics Statistics

    Share Statistics

    Protagonist Therapeutics has 61.98M shares outstanding. The number of shares has increased by 4.66% in one year.

    Shares Outstanding

    n/a
    		 61.98M

    Shares Change (YoY)

    n/a
    		 4.66%

    Shares Change (QoQ)

    n/a
    		 3%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 58.31M

    Failed to Deliver (FTD) Shares

    n/a
    		 85

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 5.21M, so 8.4% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.21M

    Short % of Shares Out

    n/a
    		 8.4%

    Short % of Float

    n/a
    		 10.08%

    Short Ratio (days to cover)

    n/a
    		 7.58

    Valuation Ratios

    The PE ratio is 8.64 and the forward PE ratio is -939.33. Protagonist Therapeutics's PEG ratio is -0.02.

    PE Ratio

    n/a
    		 8.64

    Forward PE

    n/a
    		 -939.33

    PS Ratio

    n/a
    		 5.47

    Forward PS

    n/a
    		 7.1

    PB Ratio

    n/a
    		 3.52

    P/FCF Ratio

    n/a
    		 13

    PEG Ratio

    n/a
    		 -0.02
    Financial Ratio History

    Enterprise Valuation

    Protagonist Therapeutics has an Enterprise Value (EV) of 2.29B.

    EV / Sales

    n/a
    		 5.27

    EV / EBITDA

    n/a
    		 9.06

    EV / EBIT

    n/a
    		 12.44

    EV / FCF

    n/a
    		 12.53

    Financial Position

    The company has a current ratio of 12.48, with a Debt / Equity ratio of 0.02.

    Current Ratio

    n/a
    		 12.48

    Quick Ratio

    n/a
    		 12.48

    Debt / Equity

    n/a
    		 0.02

    Debt / EBITDA

    n/a
    		 0.04

    Debt / FCF

    n/a
    		 0.06

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is 40.75% and Return on Invested Capital is 35.69%.

    Return on Equity

    n/a
    		 40.75%

    Return on Assets

    n/a
    		 36.95%

    Return on Invested Capital

    n/a
    		 35.69%

    Revenue Per Employee

    n/a
    		 $3,503,491.94

    Profits Per Employee

    n/a
    		 $2,219,258.06

    Employee Count

    n/a
    		 124

    Asset Turnover

    n/a
    		 0.58

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 4.22M

    Effective Tax Rate

    n/a
    		 1.51%

    Stock Price Statistics

    The stock price has increased by 68.34% in the last 52 weeks. The beta is 2.25, so Protagonist Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.25

    52-Week Price Change

    n/a
    		 68.34%

    50-Day Moving Average

    n/a
    		 46.88

    200-Day Moving Average

    n/a
    		 44.07

    Relative Strength Index (RSI)

    n/a
    		 65.87

    Average Volume (20 Days)

    n/a
    		 1,062,592

    Income Statement

    In the last 12 months, Protagonist Therapeutics had revenue of 434.43M and earned 275.19M in profits. Earnings per share was 4.47.

    Revenue

    n/a
    		 434.43M

    Gross Profit

    n/a
    		 431.47M

    Operating Income

    n/a
    		 252.84M

    Net Income

    n/a
    		 275.19M

    EBITDA

    n/a
    		 252.84M

    EBIT

    n/a
    		 252.84M

    Earnings Per Share (EPS)

    n/a
    		 4.47
    Full Income Statement

    Balance Sheet

    The company has 97.25M in cash and 10.87M in debt, giving a net cash position of 86.38M.

    Cash & Cash Equivalents

    n/a
    		 97.25M

    Total Debt

    n/a
    		 10.87M

    Net Cash

    n/a
    		 86.38M

    Retained Earnings

    n/a
    		 -340.52M

    Total Assets

    n/a
    		 742.13M

    Working Capital

    n/a
    		 570.75M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 184.15M and capital expenditures -1.35M, giving a free cash flow of 182.8M.

    Operating Cash Flow

    n/a
    		 184.15M

    Capital Expenditures

    n/a
    		 -1.35M

    Free Cash Flow

    n/a
    		 182.8M

    FCF Per Share

    n/a
    		 2.97
    Full Cash Flow Statement

    Margins

    Gross margin is 99.32%, with operating and profit margins of 58.2% and 63.34%.

    Gross Margin

    n/a
    		 99.32%

    Operating Margin

    n/a
    		 58.2%

    Pretax Margin

    n/a
    		 64.32%

    Profit Margin

    n/a
    		 63.34%

    EBITDA Margin

    n/a
    		 58.2%

    EBIT Margin

    n/a
    		 58.2%

    FCF Margin

    n/a
    		 42.08%

    Dividends & Yields

    PTGX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 11.58%

    FCF Yield

    n/a
    		 7.69%
    Dividend Details

    Analyst Forecast

    The average price target for PTGX is $65, which is 18.9% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $65

    Price Target Difference

    n/a
    		 18.9%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 9
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 33.21

    Graham Upside

    n/a
    		 -39.24%

    Scores

    Altman Z-Score

    n/a
    		 33.99

    Piotroski F-Score

    n/a
    		 6

    Add to Watchlist